Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

Baylor College of Medicine, Houston, Texas, United States
Blood (Impact Factor: 9.78). 08/2006; 108(2):441-51. DOI: 10.1182/blood-2005-07-3011
Source: PubMed

ABSTRACT Infant acute lymphoblastic leukemia (ALL) has a poor therapeutic outcome despite attempts to treat it based on prognostic factor-guided therapy. This is the first cooperative group trial characterizing all infants at the molecular level for MLL/11q23 rearrangement. All infants enrolled on Children's Cancer Group (CCG) 1953 were tested for MLL rearrangement by Southern blot and the 11q23 translocation partner was identified (4;11, 9;11, 11;19, or "other") by reverse-transcriptase polymerase chain reaction (PCR). One hundred fifteen infants were enrolled; overall event-free survival (EFS) was 41.7% (SD = 9.2%) and overall survival (OS) was 44.8% at 5 years. Five-year EFS for MLL-rearranged cases was 33.6% and for MLL-nonrearranged cases was 60.3%. The difference in EFS between the 3 major MLL rearrangements did not reach statistical significance. Multivariate Cox regression analyses showed a rank order of significance for negative impact on prognosis of CD10 negativity, age younger than 6 months, and MLL rearrangement, in that order. Toxicity was the most frequent cause of death. Relapse as a first event in CCG 1953 was later (median, 295 days) compared with CCG 1883 historic control (median, 207 days). MLL/11q23 rearrangement, CD10 expression, and age are important prognostic factors in infant ALL, but molecular 11q23 translocation partners do not predict outcome.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Translocation of mixed-lineage leukemia (MLL) gene with AF4, AF9 or ENL results in acute leukemia with both lymphoid and myeloid involvement. We characterized leukemia-initiating cells (LICs) in primary infant MLL-rearranged leukemia using a xenotransplantation model. In MLL-AF4 patients, CD34+CD38+CD19+ and CD34-CD19+ cells initiated leukemia, and in MLL-AF9 patients, CD34-CD19+ cells were LICs. In MLL-ENL patients, either CD34+ or CD34- cells were LICs, depending on the pattern of CD34 expression. In contrast, in patients with these MLL translocations, CD34+CD38-CD19-CD33- cells were enriched for normal hematopoietic stem cells (HSCs) with in vivo long-term multi-lineage hematopoietic repopulation capacity. While LICs developed leukemic cells with clonal immunoglobulin heavy-chain (IGH) rearrangement in vivo,CD34+CD38-CD19-CD33- cells repopulated recipient bone marrow and spleen with B cells showing broad polyclonal IGH rearrangement and recipient thymus with CD4+ single positive, CD8+ single positive and CD4+CD8+ double positive T cells. Global gene expression profiling revealed that CD9, CD32, and CD24 were over-represented in MLL-AF4, MLL-AF9 and MLL-ENL LICs compared with normal HSCs. In patient samples, these molecules were expressed in CD34+CD38+ and CD34- LICs but not in CD34+CD38-CD19-CD33- HSCs. Identification of LICs and LIC-specific molecules in primary human MLL-rearranged ALL may lead to improved therapeutic strategies for MLL-rearranged leukemia. Copyright © 2014 American Society of Hematology.
    Blood 12/2014; 125(6). DOI:10.1182/blood-2014-03-563304 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute lymphoblastic leukemia (ALL) is the most common pediatric oncologic diagnosis, and advances in its treatment have led to progressive improvements in survival. The 4 main components of therapy are remission induction, consolidation, maintenance, and central nervous system-directed therapy, and usually last 2 to 3 years. Treatment intensity based on risk-based stratification is the cornerstone of treatment. Patients with features of more favorable disease are spared the more toxic effects of chemotherapy, whereas more aggressive regimens are reserved for those with higher-risk disease. Prognosis of relapsed pediatric ALL depends primarily on duration of remission and site of relapse. Copyright © 2015 Elsevier Inc. All rights reserved.
    Pediatric Clinics of North America 02/2015; 62(1):61-73. DOI:10.1016/j.pcl.2014.09.006 · 2.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Global death toll of Acute Leukemia (AL), as a heterogeneous group of hematopoietic malignancies, is rather high, i.e. almost 74% of 300,000 new cases die every year. This reflects a poor prognosis of this malignancy in most parts of the world, where contemporary and rather complex remedies are not available. There are a few well documented reports about the epidemiologic features of AL at national level in Iran. This retrospective study demonstrates demographic and laboratory features of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) patients admitted to the main referral oncology hospitals in the ex-Iran University of Medical Sciences in Tehran (Firoozgar and Rasoul-Akram hospitals) during the last decade (2001-2011). Medical records of all patients admitted to the both hospitals diagnosed with AML and ALL were reviewed during the study period for demographic, biological and clinical characteristics at diagnosis. Four-hundred fifty five patients were diagnosed with AML and ALL, who admitted to the both hospitals during ten years, of whom 59.6 % (271 patients) were male. Fifty five percent of patients had AML and 44.6 % had ALL, both significantly dominated in men (p<0.001). AML patients died more significantly (p<0.05) and the most deaths occurred in older patients (p<0.001). Initial WBC count was significantly related to death (p= 0.001), where the least death (13%) occurred in the group with initial WBC between 5-10×10(3)/μL and most of deceased had an initial WBC more than 10×10(3)/μL. Logistic regression showed that age, fever and WBC were significant prognostic factors. Demographic characteristics of AL patients were almost the same as other global reports. Most deaths occurred in older patients, those who had fever, and patients with higher WBC count at first admission, which warrants more investigations accurately and also improvements in hospital records.
    Iranian Journal of Cancer Prevention 04/2012; 5(3):157-63.